bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Go back to bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions| BLUEBIRD BIO (NASDAQ: BLUE) | Delayed: 4.97 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.97 | 52 Week High | $95.28 | |||
| Open | $4.97 | 52 Week Low | $35.37 | |||
| Day High | $4.97 | P/E | N/A | |||
| Day Low | $4.97 | EPS | $-1.81 | |||
| Volume | 4,146,251 | |||||
